Partnering with experts for diagnostic accuracy
Due to their rarity and histological mimics, up to 40% of desmoid tumors are initially misdiagnosed.2 Once a desmoid tumor is suspected, guidelines recommend initial evaluation and management by a multidisciplinary team with desmoid tumor expertise.3,4 Collaborating with these specialists can help improve patient outcomes and quality of life.5,6
Explore the topics below to learn more about desmoid tumor diagnosis, management, and patient resources.
Before making a treatment decision, consider consulting with a desmoid tumor expert
The websites listed above provide additional information if you are interested in submitting your patient cases to SARC or DTRF to be considered for review by a tumor board with desmoid tumor expertise.
The SARC Tumor Board and DTRF Virtual Tumor Board are independent of SpringWorks Therapeutics, Inc. Inclusion of these resources does not represent an endorsement or recommendation from SpringWorks Therapeutics for any group or organization. SpringWorks Therapeutics has no control over whether any case will be considered for review by a tumor board.
Location-specific ICD-10-CM codes for desmoid tumors went into effect on October 1, 2023.7 These diagnosis codes can be incorporated into your clinical practice.
Sign up for information
ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.
- Lazcano CS, Gronchi A. Surgical management of desmoid tumors—patient selection, timing, and approach. Curr Oncol. 2025;32(7):408.
- Kasper B, Baumgarten C, Garcia J, et al. Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408.
- Kasper B, Baldini EH, Bonvalot S, et al; Desmoid Tumor Working Group. Current management of desmoid tumors: a review. JAMA Oncol. Accessed May 21, 2026. https://jamanetwork.com/journals/jamaoncology/article-abstract/2820212.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 29, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27(3):965-980.
- Joglekar SB, Rose PS, Sim F, Okuno S, Petersen I. Current perspectives on desmoid tumors: the Mayo Clinic approach. Cancers (Basel). 2011;3(3):3143-3155.
- Centers for Medicare & Medicaid Services 2024 ICD-10-CM codes. Centers for Medicare & Medicaid Services Web Site. Accessed May 21, 2026. https://www.cms.gov/medicare/icd-10/2024-icd-10-cm.